ArticleBMC microbiology2018
The therapeutic potential of bacteriophages targeting gram-negative bacteria using Galleria mellonella infection model.
Article in BMC microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 91 citations in OpenAlex.
- Comparison and correlation of in vitro and in vivo approaches for determining Pseudomonas aeruginosa bacteriophages activity.BMC microbiology · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Characterization of the bacteriophage vB_KpnP_Henu1_3 lytic for K1Microbiology spectrum · 2026Article
- Broad-spectrum phage cocktail targetingFrontiers in microbiology · 2026Article
- In Vivo Evaluation of Efficacy and Toxicity of Bioinspired Peptides With Antimicrobial Properties Against Fungal Infection inInternational journal of microbiology · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Pedal effect: aerobic and facultative anaerobic Enterobacter hormaechei maintain the homeostasis of the house fly gut microbiota under different oxygen conditions.Parasites & vectors · 2025Article
- Isolation and characterization of an antibiofilm bacteriophage against Klebsiella michiganensis and evaluation of its therapeutic potential in an insect larval gut colonization model.BMC microbiology · 2025Article
- Isolation and characterization of strictly lytic bacteriophages against carbapenem-resistantMicrobiology spectrum · 2025Article
- Phage therapy for antimicrobial-resistant Klebsiella spp. infections: a review of mechanisms, synergies, and clinical potential.Archives of microbiology · 2025Review
- Characterization and genomics of phage Henu2_3 against K1 Klebsiella pneumoniae and its efficacy in animal models.AMB Express · 2025Article
- Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2025Review
- Bacteriophage therapy: a possible alternative therapy against antibiotic-resistant strains ofFrontiers in microbiology · 2025Review
- Isolation, characterization, therapeutic and prophylactic applications of a lytic bacteriophage to combat multi-drug resistance Shigella flexneri: an animal study model.GMS hygiene and infection control · 2025Article
- Use of Galleria mellonella as an Animal Model for Studying the Antimicrobial Activity of Bacteriophages with Potential Use in Phage Therapy.Methods in molecular biology (Clifton, N.J.) · 2024Article
- The applications of animal models in phage therapy: An update.Human vaccines & immunotherapeutics · 2023Review
- Freeze-Drying of Encapsulated Bacteriophage T4 to Obtain Shelf-Stable Dry Preparations for Oral Application.Pharmaceutics · 2023Article
- Resistance ofMicrobiology spectrum · 2023Article
- New Bacteriophages Members of thePHAGE (New Rochelle, N.Y.) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhage therapy is the therapeutic use of bacteriophages to treat highly drug resistant bacterial infections. The current surge in bacteriophage therapy is motivated mainly because of the emergence of antibiotic-resistant bacteria in clinics. This study evaluated the therapeutic potential of three bacteriophages isolated against Escherichia coli ec311, Klebsiella pneumoniae kp235 and Enterobacter cloacae el140 strains using Galleria mellonella. The in vitro activity of three different phages belonging to Podoviridae and Myoviridae families was studied by the double agar overlay method against multi-drug resistant strains. Larval survivability studies were performed to evaluate the potential of phages against infection using G. mellonella.
resultsAll the three phages were found to have potential to infect the host bacterial strains. For in vivo studies it was observed that E. coli and E. cloacae infected larvae, should be treated with three phage doses (20 μL, 10
conclusionOur data shows that although in vitro studies showed high infectivity of phages, for in vivo models multiple phage doses were required for effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.